Skip to main content

Provectus Biopharmaceuticals, Inc.

PVCT
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0000315545

No open-market purchases or sales by Provectus Biopharmaceuticals, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $8.97K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Provectus Biopharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Provectus Biopharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Provectus Biopharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Pershing EdwardCEO–Sep 18, 202637
Rodrigues DominicPRESIDENT–Jun 30, 20261
Lacey John IIIDirector–Jun 30, 20261
Bailey WebsterDirector–Jun 30, 20261
Wachter Eric PhDCTO–Dec 4, 20240
Raines HeatherCFO–Dec 4, 20240
Morris Jeffrey Allen10% Owner4,260,061Aug 14, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 11, 2026 (view filing)Feb 92 daysPershing EdwardCEOPPurchase+349.4K$0.286+$99.9K–2.61M afterDerivative
Nov 25, 2024 (view filing)Nov 223 daysPershing EdwardCEOPPurchase+803.6K$0.286+$229.8K–1.69M afterDerivative
Oct 19, 2023 (view filing)5:16 PM ETOct 316 daysLatePershing EdwardDirectorPPurchase+193.1K$0.2862+$55.3K–690.8K afterDerivative
Sep 20, 2022 (view filing)5:26 PM ETSep 164 daysRodrigues DominicDirectorPPurchase+11.4M$0.2862+$3.27M–11.4M afterDerivative